Quimi Daphne 4

What Happened Daphne Quimi, a director of Amylyx Pharmaceuticals, was granted a derivative award on 2026-06-04 covering 24,372 shares. The filing records the acquisition price as $0.00 (derivative security); the award is not an open-market purchase or sale and does not represent immediate cash paid or proceeds received.

Key Details

• Transaction date: 2026-06-04; Form 4 filed: 2026-06-08 (no late-filing indicator provided in the supplied data).
• Security type: Derivative award (option) covering 24,372 shares; reported price $0.00.
• Vesting: Award vests in full on the earlier of (i) June 4, 2027 or (ii) the date of the next annual meeting, subject to Quimi’s continuous service. (Footnote from filing.)
• Shares owned following the transaction: Not specified in the provided filing excerpt.
• Transaction code: A (award/grant).

Context This was a grant of a derivative award (an option) rather than a purchase or sale—meaning Quimi received the right to shares that vest in the future and are contingent on continued service. Such awards are common for directors as compensation and do not by themselves indicate immediate buying or selling activity.